Oculis Holding AG (OCS) Common Equity (2021 - 2026)
Oculis Holding AG (OCS) recorded quarterly Common Equity of $251.1 million in Q1 2026, up 2.37% quarter-over-quarter from $245.3 million in Q4 2025, and up 38.83% on a YoY basis from $180.9 million in Q1 2025.
Oculis Holding AG (OCS) Common Equity (2021 - 2026) Analysis & Trends
Oculis Holding AG's Common Equity history runs 6 years deep, the most recent figure standing at $251.1 million for Q1 2026.
- In Q1 2026, Common Equity rose 38.83% year-over-year to $251.1 million; the TTM figure through Mar 2026 stood at $251.1 million (up 38.83% YoY), while the FY2025 annual figure was $245.3 million, up 192.85% from the prior year.
- Common Equity was $251.1 million for Q1 2026 at Oculis Holding AG, up from $245.3 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $251.1 million in Q1 2026 to a low of -$101.7 million in Q4 2022.
- Historically, Common Equity has averaged $128.9 million across 5 years, with a median of $124.8 million in 2024.
- The sharpest annual moves came in 2022 and 2023: Common Equity sank 53.87% in 2022, then soared 203.88% in 2023.
- A 5-year view of Common Equity shows it stood at -$101.7 million in 2022, then jumped by 203.88% to $105.7 million in 2023, then declined by 20.72% to $83.8 million in 2024, then surged by 192.85% to $245.3 million in 2025, then increased by 2.37% to $251.1 million in 2026.
- The last three Common Equity figures came in at $251.1 million (Q1 2026), $245.3 million (Q4 2025), and $163.3 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | 35.63 Mn |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | -1.42 Mn |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | 14.38 Mn |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | 13.21 Mn |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | 11.87 Mn |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 19.36 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | - |
| 10 | Oculis Holding AG | 8.23 Bn | 7.92 Bn | - | 251.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 251.12 Mn |
| Dec 31, 2025 | 245.32 Mn |
| Sep 30, 2025 | 163.26 Mn |
| Jun 30, 2025 | 172.84 Mn |
| Mar 31, 2025 | 180.88 Mn |
| Dec 31, 2024 | 83.77 Mn |
| Sep 30, 2024 | 109.91 Mn |
| Jun 30, 2024 | 124.76 Mn |
| Mar 31, 2024 | 90.55 Mn |
| Dec 31, 2023 | 105.66 Mn |
| Sep 30, 2023 | 119.56 Mn |
| Jun 30, 2023 | 130.34 Mn |
| Dec 31, 2022 | -101.72 Mn |
| Dec 31, 2021 | -66.11 Mn |